Document:

EX-4.1

 Exhibit 4.1 

FIRST AMENDMENT TO 

RIGHTS AGREEMENT 
 This
First Amendment to Rights Agreement, effective as of February 27, 2014 (the “Amendment”), amends the Rights Agreement, dated as of July 13, 2005 (the “Rights Agreement”), between Alnylam Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., f/k/a Equiserve Trust Company, N.A., a national banking association (the “Rights Agent”). Capitalized terms used herein but not
defined herein shall have their defined meanings set forth in the Rights Agreement. 
 WHEREAS, pursuant to the Stock Purchase Agreement
between the Company and Genzyme Corporation, a Massachusetts corporation (the “Investor”), dated as of January 11, 2014, the Investor is acquiring 8,766,338 shares (the “Initial Shares”), or approximately 12%,
of the outstanding common stock, par value $.01 per share (the “Common Stock”), of the Company as of the date thereof and after giving effect to such stock issuance; 

WHEREAS, pursuant to the Investor Agreement by and between the Company and the Investor, dated as of February 27, 2014 (the
“Investor Agreement”), the Company desires to amend the Rights Agreement to provide that the Investor and its Affiliates and Associates may acquire and beneficially own additional shares of Common Stock (together with the Initial
Shares, the “Shares”) without becoming Acquiring Persons (as defined in the Rights Agreement), consistent with the terms of the Investor Agreement (the “Exemption”); 

WHEREAS, as a condition to the willingness of the Company to agree to provide the Exemption to the Investor, the Investor has agreed to take
certain actions and forebear from taking certain other actions, as set forth in the Investor Agreement; 
 WHEREAS, pursuant to
Section 27 of the Rights Agreement and under the circumstances specified therein, the Company and the Rights Agent shall, if the Company so directs, supplement or amend any provision of the Rights Agreement in any respect without the approval
of any holders of the Rights; 
 WHEREAS, the Company now desires to amend the Rights Agreement as set forth in this Amendment, and pursuant
to Section 27 of the Rights Agreement, the Company hereby directs that the Rights Agreement should be amended as set forth in this Amendment; and 

WHEREAS, the Board has determined that this Amendment and the transactions contemplated hereby are advisable and in the best interests of the
Company and the holders of Common Stock. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Section 1 of the Rights Agreement is hereby amended by adding the following definitions: 

(nn) “Genzyme Entities” shall mean Genzyme Corporation and its Affiliates and Associates. 

 (oo) “Investor Agreement” shall mean the Investor Agreement, dated
February 27, 2014, by and between Genzyme Corporation and the Company. 
 (pp) “Standstill Limit” shall have the
meaning set forth in the Investor Agreement. 
 (qq) “Standstill Term” shall have the meaning set forth in the Investor
Agreement. 
 2. The definition of “Acquiring Person” in Section 1(a) of the Rights Agreement is hereby amended and
restated in its entirety to read as follows: 
 “Acquiring Person” shall mean any Person who or which, together with all
Affiliates and Associates of such Person, shall be the Beneficial Owner of 20% or more of the shares of Common Stock then outstanding, but shall not include (i) the Company, (ii) any Subsidiary of the Company, (iii) any employee
benefit plan of the Company or of any Subsidiary of the Company or (iv) any Person organized, appointed or established by the Company for or pursuant to the terms of any such plan. Notwithstanding the foregoing, (x) no Person shall become
an “Acquiring Person” as the result of an acquisition of Common Stock by the Company which, by reducing the number of shares outstanding, increases the proportionate number of shares Beneficially Owned by such Person to 20% or more of the
shares of Common Stock of the Company then outstanding; provided, however that if a Person shall become the Beneficial Owner of 20% or more of the shares of Common Stock of the Company then outstanding as the result of an acquisition
of Common Stock by the Company and shall, following written notice from, or public disclosure by the Company of such share purchases by the Company become the Beneficial Owner of any additional Common Stock of the Company and shall then Beneficially
Own 20% or more of the shares of Common Stock then outstanding, then such Person shall be deemed to be an “Acquiring Person”, (y) if the Board determines in good faith that a Person who would otherwise be an “Acquiring
Person,” as defined pursuant to the foregoing provisions of this paragraph (a), has become such inadvertently, and such Person divests as promptly as practicable (as determined in good faith by the Board of Directors) following receipt of
written notice from the Company of such event, of Beneficial Ownership of a sufficient number of shares of Common Stock so that such Person would no longer be an “Acquiring Person,” as defined pursuant to the foregoing provisions of this
paragraph (a), then such Person shall not be deemed to be an “Acquiring Person” for any purposes of this Agreement unless and until such Person shall again become an “Acquiring Person” and (z) the term “Acquiring
Person” shall not include (i) during the Standstill Term (as it may be reinstated pursuant to the proviso in Section 1(ppp) of the Investor Agreement or extended pursuant to Section 3.2(c) of the Investor Agreement), the Genzyme
Entities provided and only for so long as the Genzyme Entities do not collectively Beneficially Own shares of Common Stock of the Company in excess of the Standstill Limit (as 

  
 2 

 
adjusted pursuant to Section 3.2(c) of the Investor Agreement and except as otherwise permitted by the proviso in Section 3.1(a) of the Investor Agreement) and (ii) after the
Standstill Term, in the event that the Genzyme Entities collectively Beneficially Own 20% or more of the then outstanding shares of Common Stock of the Company as of the expiration or termination of the Standstill Term (including any reinstated
Standstill Term pursuant to the proviso in Section 1(ppp) of the Investor Agreement), the Genzyme Entities but only so long as they collectively Beneficially Own a number of shares of Common Stock of the Company equal to the number of shares of
Common Stock of the Company collectively Beneficially Owned by the Genzyme Entities as of the expiration or termination of the Standstill Term minus any shares of Common Stock of the Company thereafter sold, transferred or otherwise disposed of by a
Genzyme Entity plus any additional shares of Common Stock of the Company acquired by a Genzyme Entity solely as provided by Section 6 of the Investor Agreement until such right shall have terminated in accordance with the terms of the Investor
Agreement. For the avoidance of doubt, if after expiration or termination of the Standstill Term the Genzyme Entities shall collectively Beneficially Own less than 20% of the shares of Common Stock of the Company then outstanding and no longer have
the right pursuant to Section 6 of the Investor Agreement to acquire additional shares of Common Stock of the Company that would permit the Genzyme Entities to maintain Beneficial Ownership of Common Stock of the Company equal to 20% or more of
the shares then outstanding, then the exclusion of the Genzyme Entities from the definition of “Acquiring Person” provided in the foregoing clause (z)(ii) shall terminate. 

3. Section 3(a) of the Rights Agreement is hereby amended and restated in its entirety to read as follows: 

Until the earlier of (i) the close of business on the tenth Business Day (or such later date as may be determined by the Board) after the
Stock Acquisition Date (or, if the tenth Business Day after the Stock Acquisition Date occurs before the Record Date, the close of business on the Record Date), or (ii) the close of business on the tenth Business Day (or such later date as may
be determined by action of the Board) after the date that a tender or exchange offer (other than a Permitted Offer) is first published or sent or given within the meaning of Rule 14d-2 of the General Rules and Regulations under the Exchange Act, by
(A) any Person (other than the Company, any Subsidiary of the Company, any employee benefit plan of the Company or of any Subsidiary of the Company, any Person organized, appointed or established by the Company for or pursuant to the terms of
any such plan, or, during the Standstill Term (as it may be reinstated pursuant to the proviso in Section 1(ppp) of the Investor Agreement or extended pursuant to Section 3.2(c) of the Investor Agreement), the Genzyme Entities) if upon
consummation thereof, such Person would be the Beneficial Owner of 20% or more of the shares of Common Stock then outstanding, or (B) the Genzyme Entities, during the Standstill Term (as it may be reinstated pursuant to the proviso in
Section 1(ppp) of the Investor Agreement or extended pursuant to Section 3.2(c) of the Investor Agreement), if upon consummation thereof the Genzyme Entities would collectively Beneficially Own shares of Common Stock of the Company in
excess of the Standstill Limit (as adjusted pursuant to Section 3.2(c) 

  
 3 

 
of the Investor Agreement) (the earlier of (i) and (ii) being herein referred to as the “Distribution Date”), (x) the Rights will be evidenced by the certificates for the
Common Stock registered in the names of the holders of the Common Stock (which certificates for Common Stock shall be deemed also to be certificates for Rights) and not by separate certificates, and (y) the Rights will be transferable only in
connection with the transfer of the underlying shares of Common Stock (including a transfer to the Company). As soon as practicable after the Distribution Date, the Rights Agent will send by first-class, insured, postage prepaid mail, to each record
holder of the Common Stock as of the close of business on the Distribution Date, at the address of such holder shown on the records of the Company, one or more rights certificates, in substantially the form of Exhibit B hereto (the “Rights
Certificates”), evidencing one Right for each share of Common Stock so held, subject to adjustment as provided herein. With respect to certificates for the Common Stock outstanding as of the close of business on the Record Date, until the
Distribution Date, the Rights will be evidenced by such certificates for the Common Stock and the registered holders of the Common Stock shall also be the registered holders of the associated Rights. In addition, in connection with the issuance or
sale of shares of Common Stock following the Distribution Date and prior to the redemption or expiration of the Rights, the Company (i) shall, with respect to shares of Common Stock so issued or sold pursuant to the exercise of stock options or
under any employee benefit plan or arrangement, or upon the exercise, conversion or exchange of securities granted or issued by the Company prior to the Distribution Date, and (ii) may, in any other case, if deemed necessary or appropriate by
the Board, issue Rights Certificates representing the appropriate number of Rights in connection with such issuance or sale; provided, however, that (x) no such Rights Certificate shall be issued if, and to the extent that, the Company shall be
advised by counsel that such issuance would create a significant risk of material adverse tax consequences to the Company or the Person to whom such Rights Certificate would be issued, and (y) no such Rights Certificate shall be issued if, and
to the extent that, appropriate adjustment shall otherwise have been made in lieu of the issuance thereof. In the event that an adjustment in the number of Rights per share of Common Stock has been made pursuant to Sections 11(i) or 11(p) hereof, at
the time of distribution of the Rights Certificates, the Company shall make the necessary and appropriate rounding adjustments (in accordance with Section 14(a) hereof) so that Rights Certificates representing only whole numbers of Rights are
distributed and cash is paid in lieu of any fractional Rights. As of and after the Distribution Date, the Rights will be evidenced solely by such Rights Certificates. 

4. Except as expressly set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend or in any way affect any of
the terms, conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect and shall be otherwise unaffected. 

5. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, United States of America,
applicable to contracts made and to be performed entirely within such State, without regard to conflict-of-law principles. 

  
 4 

 6. This Amendment may be executed in any number of counterparts and each of such
counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. A signature to this Amendment transmitted electronically shall have the same authority, effect, and
enforceability as an original signature. 
 [The remainder of this page has been intentionally left blank] 

  
 5 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed as of the day and year first above
written. 
  

									
		 		 	ALNYLAM PHARMACEUTICALS, INC.
				
	Attest:	 		 		 	
				
	 /s/ Mary Beth DeLena
	 		 	By:	 	 /s/ John M. Maraganore

	Name:	 	Mary Beth DeLena	 		 	Name:	 	John M. Maraganore
	Title:	 	Vice President, AGC	 		 	Title:	 	Chief Executive Officer
				
		 		 		 	COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent
				
	Attest:	 		 		 	
				
	 /s/ Amy E. Walden
	 		 	By:	 	 /s/ Dennis V. Moccia

	Name:	 	Amy E. Walden	 		 	Name:	 	Dennis V. Moccia
	Title:	 	Contract Negotiation Specialist	 		 	Title:	 	Manager, Contract Administration

 [Signature Page to First Amendment to Rights Agreement]EX-10.1

 Exhibit 10.1 

AMENDMENT NO. 2 TO CREDIT AGREEMENT 

AMENDMENT NO. 2 TO CREDIT AGREEMENT, dated as of February 24, 2014 (this “Amendment”), among BIG
HEART PET BRANDS (formerly known as Del Monte Corporation), a Delaware corporation as successor by merger to Del Monte Foods Company (the “Borrower”), Blue Acquisition Group, Inc. (“Holdings”), each of the
lenders that is a signatory hereto; and JPMORGAN CHASE BANK, N.A., as administrative agent and collateral agent (in such capacity, together with its successors, the “Administrative Agent”). 

W I T N E S S E T H: 

WHEREAS, the Borrower, Holdings, the Administrative Agent and each lender from time to time party thereto (the
“Lenders”) have entered into a Credit Agreement, dated as of March 8, 2011 (as amended by Amendment No. 1 dated as of February 5, 2013, the “Credit Agreement”) (capitalized terms not otherwise defined
in this Amendment have the same meanings as specified in the Credit Agreement); 
 WHEREAS, the Borrower intends to make a
prepayment of Initial Terms Loans from the proceeds of the Consumer Products Asset Sale (as defined herein) in an aggregate amount of $881,000,000 in accordance with Section 5.2(a) of the Credit Agreement on the Amendment No. 2 Effective
Date; 
 WHEREAS, Section 13.1 of the Credit Agreement permits amendment of the Credit Agreement with the consent of
the Administrative Agent, the Borrower and the Lenders providing the replacement term loan tranche to permit the refinancing of all outstanding Initial Term Loans of any Class with a replacement term loan tranche thereunder; 

WHEREAS, J.P. Morgan Securities LLC and KKR Capital Markets LLC will act as joint lead arrangers and joint bookrunners under
the Amended Credit Agreement (as defined below) and this Amendment; 
 WHEREAS, upon the effectiveness of this Amendment,
each Lender that shall have executed and delivered a signature page to this Amendment (a “Consent”) under the “Cashless Settlement Option” (each, a “Cashless Option Lender”) shall be deemed to have
converted all (or such lesser amount as the Administrative Agent may allocate) of its Initial Term Loans under the Credit Agreement (which existing Initial Term Loans shall thereafter no longer be deemed to be outstanding) into Initial Term Loans
under the Credit Agreement, as amended by this Amendment (the “Amended Credit Agreement”), in the same aggregate principal amount as such Lender’s Initial Term Loans under the Credit Agreement (or such lesser amount as the
Administrative Agent may allocate), and thereafter be a Lender under the Amended Credit Agreement and shall be deemed to have consented to the Amendment; 

WHEREAS, pursuant to Section 13.1 of the Credit Agreement, the Loan Parties and Required Lenders wish to make certain
other amendments to the Credit Agreement; 
 WHEREAS, the Administrative Agent and the Lenders signatory hereto are willing
to so agree pursuant to Section 13.1 of the Credit Agreement, subject to the conditions set forth herein; 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the sufficiency and receipt of
all of which is hereby acknowledged, the parties hereto hereby agree as follows: 

 SECTION 1.        Amendments. 

(a)        The following defined terms are hereby added to Section 1.1 of
the Credit Agreement in alphabetical order: 
   “Amendment No. 2” shall
mean Amendment No. 2 to this Agreement dated as of February 24, 2014. 

  “Amendment No. 2 Effective Date” shall mean February 24, 2014, the date
on which the conditions precedent set forth in Section 3 of Amendment No. 2 are satisfied. 

  “Cashless Settlement Option” shall have the meaning assigned to such term in the
Consent (as such term is defined in Amendment No. 2) to Amendment No. 2. 

  “Consumer Products Asset Sale” means the sale of the Borrower’s consumer
products business to Del Monte Pacific Limited pursuant to that certain Purchase Agreement dated October 9, 2013. 

  “Consumer Products Asset Sale Proceeds” means the Net Cash Proceeds from the
Consumer Products Asset Sale. 
   “Consumer Products Asset Sale Prepayment”
means the prepayment of $881.0 million of Initial Term Loans on the Amendment No. 2 Effective Date using the Consumer Products Asset Sale Proceeds. 

  “Impacted Interest Period” shall mean, with respect to a LIBOR Screen Rate, an
Interest Period which shall not be available at the applicable time. 
   “Interpolated
Rate” shall mean, at any time, for any Interest Period, the rate per annum (rounded to the same number of decimal places as the LIBOR Screen Rates) determined by the Administrative Agent (which determination shall be conclusive and binding
absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the LIBOR Screen Rate for the longest period (for which the LIBOR Screen Rate is available) that is shorter than the Impacted Interest
Period and (b) the LIBOR Screen Rate for the shortest period (for which the LIBOR Screen Rate is available) that exceeds the Impacted Interest Period, in each case, as of 11:00 a.m., London Time, two Business Days prior to the commencement of
such Interest Period. When determining the rate for a period which is less than the shortest period for which the LIBOR Screen Rate is available, the LIBOR Screen Rate for purposes of paragraph (a) above shall be deemed to be the overnight
screen rate where “overnight screen rate” means the overnight rate determined by the Administrative Agent from such service as the Administrative Agent may select. 

  “LIBOR Screen Rate” shall mean the London interbank offered rate administered by
the ICE Benchmark Administration (or any other Person that takes over the administration of such rate) for Dollars for a period equal in length to such Interest Period as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen or, in the event
such rate does not appear on either of such Reuters pages, on any successor or substitute page on such screen that displays such rate, or on the appropriate page of such other information service that publishes such rate as shall be selected by the
Administrative Agent from time to time in its reasonable discretion; provided, that, if any LIBOR Screen Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement. 

  
 -2- 

 (b)        The definition of
“ABR” in Section 1.1 of the Credit Agreement is hereby amended by deleting the reference to “2.00%” therein and replacing it with “1.75%”. 

(c)        The definition of “Applicable ABR Margin” in
Section 1.1 of the Credit Agreement is hereby amended and restated as follows: 

  “Applicable ABR Margin” shall mean, with respect to each ABR Loan that is an
Initial Term Loan, 1.75%. 
 (d)        The definition of “Applicable LIBOR
Margin” in Section 1.1 of the Credit Agreement is hereby amended and restated as follows: 

  “Applicable LIBOR Margin” shall mean, with respect to each LIBOR Loan that is an
Initial Term Loan, 2.75% 
 (e)        The definition of “BBA LIBOR” in
Section 1.1 of the Credit Agreement is hereby deleted. 
 (f)        The
definition of “Cashless Option Lender” in Section 1.1 of the Credit Agreement is hereby amended by replacing the reference to “Amendment No. 1” with “Amendment No. 2”. 

(g)        The definition of “Initial Term Loan Maturity Date” in Section 1.1 of
the Credit Agreement is hereby amended by replacing the reference to “March 8, 2018” with “March 8, 2020” 

(h)        The definition of “LIBOR Rate” in Section 1.1 of the
Credit Agreement is hereby deleted and replaced with the following: 
   “LIBOR
Rate” shall mean, for any Interest Period with respect to a LIBOR Loan of any currency, the LIBOR Screen Rate as of approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, for deposits in
such currency for such Interest Period; provided that if a LIBOR Screen Rate shall not be available at the applicable time for the applicable Interest Period, then the LIBOR Rate for such currency and Interest Period shall be the Interpolated
Rate; provided, further, that in no event shall the LIBOR Rate for any Interest Period at any time be less than 0.75% per annum. 

(i)        The definition of “Maximum Incremental Facilities Amount” in
Section 1.1 of the Credit Agreement is hereby amended by adding the following at the end of such definition: “, in each case, incurred pursuant to the foregoing clause (a)(i).” 

(j)        Section 2.1 of the Credit Agreement is hereby amended by adding
the following as the third paragraph with the following: 
 “Subject to and upon the terms and conditions set forth
herein, each Cashless Option Lender and JPMorgan Chase Bank, N.A. (which shall in such capacities be Lenders) agrees to make and/or convert its existing Initial Term Loans into a loan or loans to the Borrower on the Amendment No. 2 Effective
Date (which shall replace the Initial Term Loans outstanding after giving effect to the Consumer Products Asset Sale Prepayment and be considered Initial Term Loans for all purposes hereunder), in an amount equal to (x) its Cashless Settlement
Option allocation in accordance with Amendment No. 2 in the case of each Cashless Option Lender and (y) $206,277,870.68 in the case of JPMorgan Chase Bank, N.A. The initial Interest Periods for all LIBOR Rate Initial Term Loans made and/or
converted from exiting Initial Term Loans on the 

  
 -3- 

 
Amendment No. 2 Effective Date shall be the same Interest Periods applicable to the LIBOR Rate Initial Term Loans immediately prior to the Amendment No. 2 Effective Date.
Notwithstanding the foregoing, any Cashless Option Lender as defined in accordance with Amendment No. 2 shall not actually make a loan on the Amendment No. 2 Effective Date but shall be deemed to have rolled over its Initial Term Loans
outstanding after giving effect to the Consumer Products Asset Sale Prepayment under and as defined in the Credit Agreement in accordance with Amendment No. 2. 

(k)        Section 2.5(b) of the Credit Agreement is hereby amended and
restated as follows: 
 The Borrower shall repay to the Administrative Agent, in Dollars, for the benefit of the Initial
Term Loan Lenders, on each date set forth below (or, if not a Business Day, the immediately preceding Business Day) (each, an “Initial Term Loan Repayment Date”), a principal amount in respect of the Initial Term Loans equal to
(x) the outstanding principal amount of Initial Term Loans on the Amendment No. 2 Effective Date multiplied by (y) the percentage set forth below opposite such Initial Term Loan Repayment Date (each, an “Initial Term Loan
Repayment Amount”): 
  

			
	Date	  	Initial Term Loan
	June 30, 2014	  	0.25%
	September 30, 2014	  	0.25%
	December 31, 2014	  	0.25%
	March 31, 2015	  	0.25%
	June 30, 2015	  	0.25%
	September 30, 2015	  	0.25%
	December 31, 2015	  	0.25%
	March 31, 2016	  	0.25%
	June 30, 2016	  	0.25%
	September 30, 2016	  	0.25%
	December 31, 2016	  	0.25%
	March 31, 2017	  	0.25%
	June 30, 2017	  	0.25%
	September 30, 2017	  	0.25%
	December 31, 2017	  	0.25%
	March 31, 2018	  	0.25%
	June 30, 2018	  	0.25%
	September 30, 2018	  	0.25%
	December 31, 2018	  	0.25%
	March 31, 2019	  	0.25%
	June 30, 2019	  	0.25%
	September 30, 2019	  	0.25%
	December 31, 2019	  	0.25%
	Initial Term Loan Maturity Date	  	Remaining outstanding amounts

 (l)        Section 2.9 of the Credit Agreement shall be
amended by deleting the following: “nine or”. 

  
 -4- 

 (m)       Section 5.1(b) of the
Credit Agreement is hereby amended by deleting the phrase “Amendment No. 1 Effective Date” and replacing it with “Amendment No. 2 Effective Date”. 

(n)        Section 5.2(a) of the Credit Agreement shall be amended by adding the following
proviso to the end thereof: “; provided further that, within 60 days after the Amendment No. 2 Effective Date, the Borrower may use the portion of the Consumer Products Asset Sale Proceeds not otherwise applied to make the Consumer
Products Asset Sale Prepayment to prepay, redeem, defease, repurchase or acquire or retire for value the outstanding Senior Notes as of the Amendment No. 2 Effective Date and shall not be required to prepay the Term Loans with such
amount.” 
 (o)        Section 5.2(a)(ii) of the Credit Agreement shall be amended
by deleting the phrase “fiscal year ending April 29, 2012” and replacing it with “fiscal year ending April 29, 2015” 

(p)        Section 5.2(c) of the Credit Agreement shall be amended by adding the following
sentence at the end of such section: 
 “Notwithstanding anything to the contrary contained in this Section 5.2(c), the
Consumer Products Asset Sale Prepayment shall be applied (i) first to the Initial Term Loans held by Lenders that are not Cashless Option Lenders (on a pro rata basis) and (ii) second to the Initial Term Loans held by Cashless Option
Lenders as determined by the Administrative Agent in its sole discretion.” 

(q)        Section 5.2(h) of the Credit Agreement shall be amended by
adding the following sentence at the end of such section: 
 “Notwithstanding anything to the contrary contained in this
Section 5.2(h), the rights of the Term Loan Lenders to reject its pro rata share of a mandatory prepayment pursuant to this Section 5.2(h) shall not apply to the Consumer Products Asset Sale Prepayment, which shall be made on
the Amendment No. 2 Effective Date.” 

(r)         Section 9.13 of the Credit Agreement is hereby amended
and restated as follows: 
 “9.13.   Use of Proceeds. 

  (a)        The Borrower will use the proceeds of the
Initial Term Loans incurred on the Closing Date, the Senior Notes Offering and a portion of the proceeds of borrowings under the ABL Facility to effect the Transactions. 

  (b)        The Borrower will use the proceeds of the
Initial Term Loans incurred on the Amendment No. 2 Effective Date to refinance existing Initial Term Loans outstanding immediately prior to the Amendment No. 2 Effective Date. 

(s)        Section 10.5(b) of the Credit Agreement shall be amended by adding the
following clause (20) to the end thereof: “(20) within 60 days after the Amendment No. 2 Effective Date, the prepayment, redemption, defeasance, repurchase or other acquisition or retirement for value of Senior Notes outstanding as of
the Amendment No. 2 Effective Date with the portion of the Consumer Products Asset Sale Proceeds not otherwise applied to make the Consumer Products Asset Sale Prepayment;” 

SECTION 2.        Lenders.  Each Cashless Option Lender and JPMorgan
Chase Bank, N.A. hereby agrees, on the Amendment No. 2 Effective Date and on the terms and conditions set forth herein and in the Amended Credit Agreement, to make or roll over, as applicable, its Initial Term Loans

  
 -5- 

 
in accordance with Section 2.1 of the Amended Credit Agreement. Such parties shall, effective on the Amendment No. 2 Effective Date, automatically become parties to the Amended
Credit Agreement as a Lender. Each Lender under the Credit Agreement that signs a Consent agrees that to the extent its Initial Term Loans under the Credit Agreement are being repaid on the Amendment No. 2 Effective Date it waives any amounts
it may be entitled to under Section 2.11 of the Credit Agreement in connection with such repayment. 
 SECTION
3.        Conditions of Effectiveness.  This Amendment and the amendment of the Credit Agreement as set forth in Section 1 hereof shall become effective as of the first date (such date
being referred to as the “Amendment No. 2 Effective Date,” which date is February 24, 2014) when each of the following conditions shall have been satisfied: 

(a)        The Administrative Agent shall have received this Amendment, duly executed
and delivered by (A) the Borrower, (B) the Required Lenders, (C) the Cashless Option Lenders and (D) JPMorgan Chase Bank, N.A. 

(b)        The Administrative Agent shall have received, on behalf of itself, the
Collateral Agent and the Lenders, an opinion of Simpson Thacher & Bartlett LLP, counsel for the Borrower, dated the Amendment No. 2 Effective Date and addressed to the Administrative Agent, the Collateral Agent and the Lenders, in form
and substance reasonably satisfactory to the Administrative Agent. 
 (c)        The
Borrower shall have paid to the Administrative Agent for the account of each Term Loan Lender, an upfront fee equal to 0.25% of the aggregate principal amount of the Initial Term Loans held by Term Loan Lenders on the Amendment No. 2 Effective
Date. 
 (d)        Payment of all reasonable fees and expenses due to the
Administrative Agent (as agreed to in writing between the Administrative Agent and the Borrower) (including, without limitation, fees and reasonable out-of-pocket expenses of Cahill Gordon & Reindel llp, counsel to the Administrative
Agent), in each case required to be paid on the Amendment No. 2 Effective Date. Simultaneous with effectiveness, the Lenders (other than the Cashless Option Lenders (except in connection with the Consumer Products Asset Sale Prepayment) and
JPMorgan Chase Bank, N.A.) under the existing Credit Agreement shall have been paid all accrued principal and interest under the Credit Agreement. 

(e)        The representations and warranties of each Credit Party contained in
Article VIII of the Credit Agreement or in any other Credit Document shall be true and correct in all material respects (in each case, except to the extent that any representation or warranty specifically refers to an earlier date, in which case
such representation or warranty is true and correct in all material respects as of such earlier date); provided that any representation and warranty that is qualified as to “materiality”, “Material Adverse Effect” or
similar language is true and correct in all respects on such respective dates. 

(f)        No Default shall exist, or would result from the effectiveness of this
Amendment or from the application of the proceeds thereof. 
 (g)        The
Borrower shall have delivered to the Administrative Agent a completed “Life-of-Loan” Federal Emergency Management Agency Standard Flood Hazard Determination with respect to the Mortgaged Property (together with a notice about special flood
hazard area status and flood disaster assistance duly executed by the Borrower and the applicable Credit Party relating thereto) and, if any such Mortgaged Property is located in a special flood hazard area, evidence of flood insurance to the extent
required pursuant to the Credit Agreement. 
 (h)        The Borrower shall have
made the Consumer Products Asset Sale Prepayment. 

  
 -6- 

 SECTION 4.        Representations and
Warranties.  Each of Holdings and the Borrower represents and warrants as to itself as follows as of the date hereof: 

  (a)        Neither the execution, delivery or performance
of the Amendment nor compliance with the terms and provisions thereof and the other transactions contemplated hereby will (i) contravene any applicable provision of any material law, statute, rule, regulation, order, writ, injunction or decree
of any court or governmental instrumentality, (ii) result in any breach of any of the terms, covenants, conditions or provisions of, or constitute a default under, or result in the creation or imposition of (or the obligation to create or
impose) any Lien upon any of the property or assets of such Credit Party or any of such Credit Party’s Restricted Subsidiaries (other than Liens created under the Credit Documents) pursuant to, the terms of any material indenture, loan
agreement, lease agreement, mortgage, deed of trust, agreement or other material instrument to which such Credit Party or any of such Credit Party’s Restricted Subsidiaries is a party or by which it or any of its property or assets is bound
other than any such breach, default or Lien that could not reasonably be expected to result in a Material Adverse Effect or (iii) violate any provision of the certificate of incorporation, by-laws, articles or other organizational documents of
such Credit Party or any of such Credit Party’s Restricted Subsidiaries. 

  (b)        Such Credit Party has the corporate or other
organizational power and authority to execute, deliver and carry out the terms and provisions of this Amendment and has taken all necessary corporate or other organizational action to authorize the execution, delivery and performance of this
Amendment. Such Credit Party has duly executed and delivered this Amendment and this Amendment constitutes the legal, valid and binding obligation of such Credit Party enforceable in accordance with its terms, except as the enforceability thereof
may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and subject to general principles of equity. 

SECTION 5.        Further Assurances.    The Borrower
agrees, within 90 days of the Amendment No. 2 Effective Date (unless extended by the Collateral Agent in its reasonable discretion), to take such actions requested by the Collateral Agent pursuant to section 9.14(a) of the Credit Agreement in
connection with this Amendment (which, for avoidance of doubt, may include, without limitation, the execution and filing of mortgage amendments, delivery of date down title insurance endorsements and local counsel opinions, each in form and
substance reasonably acceptable to the Administrative Agent). 
 SECTION
6.        Reference to and Effect on the Credit Agreement and the Credit Documents. 

(a)        On and after the Amendment No. 2 Effective Date, each reference in the
Credit Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement, as amended by this Amendment No. 2 (i.e.,
the Amended Credit Agreement). 
 (b)        The Credit Agreement and each of the
other Credit Documents, as specifically amended by this Amendment are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. Without limiting the generality of the foregoing, the Security Documents
and all of the Collateral described therein do and shall continue to secure the payment of all Obligations of the Credit Parties under the Credit Documents, in each case, as amended by this Amendment and all guarantees and grants of security
interests are hereby reaffirmed by each Credit Party. 
 (c)        The execution,
delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative 

  
 -7- 

 
Agent under any of the Credit Documents, nor constitute a waiver of any provision of any of the Credit Documents. On and after the effectiveness of this Amendment, this Amendment shall for all
purposes constitute a Credit Document. 
 (d)        By executing and delivering a
copy of this Amendment, the Borrower hereby agrees and confirms, on behalf of itself and each other Credit Party, that all Obligations (including those created hereby) shall continue to be guaranteed and secured pursuant to the Credit Documents.

 SECTION 7.        Execution in Counterparts.  This Amendment may
be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery by facsimile or electronic transmission of an executed counterpart of a signature
page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment. 
 SECTION
8.        Governing Law; Waivers. 

(I)        THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER
SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

(II)       EACH CREDIT PARTY IRREVOCABLY AND UNCONDITIONALLY: 

  (A)       SUBMITS FOR ITSELF AND ITS PROPERTY IN ANY LEGAL
ACTION OR PROCEEDING RELATING TO THIS AMENDMENT, OR FOR THE RECOGNITION AND ENFORCEMENT OF ANY JUDGMENT IN RESPECT HEREOF, TO THE EXCLUSIVE GENERAL JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK, THE COURTS OF THE UNITED STATES OF AMERICA FOR
THE SOUTHERN DISTRICT OF NEW YORK AND APPELLATE COURTS FROM ANY THEREOF; 

  (B)       CONSENTS THAT ANY SUCH ACTION OR PROCEEDING SHALL
BE BROUGHT IN SUCH COURTS AND WAIVES ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH ACTION OR PROCEEDING IN ANY SUCH COURT OR THAT SUCH ACTION OR PROCEEDING WAS BROUGHT IN AN INCONVENIENT COURT AND AGREES NOT TO PLEAD OR
CLAIM THE SAME; 
   (C)       AGREES THAT SERVICE OF
PROCESS IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTED BY MAILING A COPY THEREOF BY REGISTERED OR CERTIFIED MAIL (OR ANY SUBSTANTIALLY SIMILAR FORM OF MAIL), POSTAGE PREPAID, TO SUCH PERSON AT ITS ADDRESS SET FORTH ON SCHEDULE 13.2 OF THE CREDIT
AGREEMENT AT SUCH OTHER ADDRESS OF WHICH THE ADMINISTRATIVE AGENT SHALL HAVE BEEN NOTIFIED PURSUANT TO SECTION 13.2 OF THE CREDIT AGREEMENT; 

  (D)       AGREES THAT NOTHING HEREIN SHALL AFFECT THE RIGHT
TO EFFECT SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR SHALL LIMIT THE RIGHT TO SUE IN ANY OTHER JURISDICTION; AND 

  
 -8- 

  (E)        WAIVES, TO THE MAXIMUM EXTENT NOT PROHIBITED
BY LAW, ANY RIGHT IT MAY HAVE TO CLAIM OR RECOVER IN ANY LEGAL ACTION OR PROCEEDING REFERRED TO IN THIS SECTION 7 ANY SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES. 

EACH CREDIT PARTY AND EACH LENDER AND AGENT IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR
PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN. 
 [The remainder of this page is intentionally left
blank] 

  
 -9- 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed
by their respective officers thereunto duly authorized, as of the date first above written. 
  

							
		 	BIG HEART PET BRANDS,
		 		 	    as Borrower

			
		 	 By:
	 	         /s/ Larry E.
Bodner

		 		 	    Name:
	 	 Larry E. Bodner

		 		 	    Title:
	 	 Executive Vice President,

		 		 		 	Chief Financial Officer and Treasurer
		
		 	 BLUE ACQUISITION GROUP, INC.,

		 		 	   as Holdings
			
		 	 By:
	 	         /s/ Larry E.
Bodner

		 		 	    Name:
	 	 Larry E. Bodner

		 		 	    Title:
	 	 Executive Vice President,

		 		 		 	Chief Financial Officer and Treasurer

  
 [Amendment No. 2] 

									
	 JPMORGAN CHASE BANK, N.A.,
	 	
	 as Administrative Agent, Collateral Agent and Lender
	 		 	
				
	 By:
	 	         /s/ Tony Yung
	 		 	
		 	    Name:
	 	 Tony Yung
	 		 	
		 	    Title:
	 	 Executive Director
	 		 	

  
 -2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]